Yissum Technology Transfer Company of the Hebrew University of Jerusalem has signed a new licensing agreement with a Belgian holding company for the commercialization of a new clean technology developed at the university.

A research group headed by Hebrew University Professor Aaron Kaplan found a solution to the growing problem of toxic algae

The OCS authorized the three-year budget, with 15M NIS secured for the first year

Protalix BioTherapeutics to Explore Biodefense and Civilian Applications with Researchers from Hebrew University of Jerusalem

The treatment was found in testing to have eliminated four different types of allergic diseases in mice.

PharmAthene's research is based on an an invention owned by Yissum

CBI will purchase 24% of the cancer-drug developer; Yissum keeps its royalties agreement

This grant was received from the World Fund for Juvenile Diabetes Research and D-Cure.

Yissum will aid Kazakhstan in establishing technology transfer facilities as part of the Kazakhstan National Center for Biotechnology.